ClinicalTrials.Veeva

Menu

Dosage of Serum Tryptase Levels in a Population of Premature Newborns to Evaluate Mast Cell Activity

C

CHU de Reims

Status

Completed

Conditions

Premature Newborns

Treatments

Biological: Additional taking blood

Study type

Interventional

Funder types

Other

Identifiers

NCT02787980
PO14087

Details and patient eligibility

About

Compare serum tryptase levels of premature babies (<37 weeks of amenorrhea) to children born at full term.

Study the evolution of serum tryptase levels in premature babies(<37 weeks of amenorrhea). Study the relationship between the onset of infectious complications, mainly the type of necrotizing enterocolitis seen in premature babies (<37 weeks of amenorrhea) and the evolution profile of serum tryptase levels.

Full description

It seems appropriate to believe that prematurity associated or not with a genetic-related sensitivity, involving several signaling pathways, makes children more vulnerable to different environmental, infectious factors that could trigger the different pathologies of premature babies. Mast cell, via its mediators, seems to play a key role.

Dosage of serum tryptase levels which is easily accessible and the work by Vitte let us imagine that the younger the child, the greater the mast cell expression, thus opening a capital pathway in the comprehension of immune system phenomena in premature babies and investigators can hope that by performing regular workups of serum tryptase levels, investigators could validate that some premature babies will express this activity in a more important manner. The relationship to eventual pathological phenomena such as necrotizing enterocolitis, but also bronchopulmonary dysplasia could then be highlighted.

Enrollment

87 patients

Sex

All

Ages

Under 1 month old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria "Patients" :

  • all premature babies (<37 weeks of amenorrhea)
  • managed in the first 24 hours of life at the Reims university hospital
  • parents accepted to participate in the research - social security card

Inclusion Criteria "Controls" :

  • children born full term, just after each "patient" child included
  • managed in the first 24 hours of life at the Reims university hospital
  • parents accepted to participate in the research.

Exclusion Criteria "Patients" and "Controls"

  • Not managed in the first 24 hours of life at the Reims University Hospital,
  • Person, who has parental authority, protected by law,
  • Newborns with a life and death emergency in the first 24 h of life,
  • Person, who has parental authority, under age 18

Trial design

Primary purpose

Diagnostic

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

87 participants in 2 patient groups

Patients = premature newborns
Other group
Description:
"Patients" will consist of all premature babies (\<37 weeks of amenorrhea), managed in the first 24 hours of life at the Reims university hospital for whom parents accepted to participate in the research Additional taking blood
Treatment:
Biological: Additional taking blood
"Controls" = children born full term
Other group
Description:
For "controls" the participation to research would be proposed to parents of children born full term, just after each "patient" child included. Additional taking blood
Treatment:
Biological: Additional taking blood

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems